CL2016002020A1 - Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor - Google Patents

Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor

Info

Publication number
CL2016002020A1
CL2016002020A1 CL2016002020A CL2016002020A CL2016002020A1 CL 2016002020 A1 CL2016002020 A1 CL 2016002020A1 CL 2016002020 A CL2016002020 A CL 2016002020A CL 2016002020 A CL2016002020 A CL 2016002020A CL 2016002020 A1 CL2016002020 A1 CL 2016002020A1
Authority
CL
Chile
Prior art keywords
plp
cofactor
erythrocytes
encapsulate
envelope
Prior art date
Application number
CL2016002020A
Other languages
English (en)
Spanish (es)
Inventor
Yann Godfrin
Vanessa Bourgeaux
Fabien Gay
Thomas Cortese
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erytech Pharma filed Critical Erytech Pharma
Publication of CL2016002020A1 publication Critical patent/CL2016002020A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01005—Tyrosine transaminase (2.6.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y404/00—Carbon-sulfur lyases (4.4)
    • C12Y404/01—Carbon-sulfur lyases (4.4.1)
    • C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
CL2016002020A 2014-02-12 2016-08-10 Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor CL2016002020A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1451100A FR3017299B1 (fr) 2014-02-12 2014-02-12 Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur

Publications (1)

Publication Number Publication Date
CL2016002020A1 true CL2016002020A1 (es) 2017-06-23

Family

ID=50729647

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002020A CL2016002020A1 (es) 2014-02-12 2016-08-10 Composición farmacéutica que consta de eritrocitos que encapsulan una encima plp dependiente y su cofactor

Country Status (17)

Country Link
US (3) US10046009B2 (enExample)
EP (2) EP3718562A1 (enExample)
JP (1) JP6563958B2 (enExample)
KR (1) KR102354103B1 (enExample)
CN (2) CN106255506B (enExample)
AU (2) AU2015217045B2 (enExample)
BR (1) BR112016017337B1 (enExample)
CA (1) CA2938469C (enExample)
CL (1) CL2016002020A1 (enExample)
ES (1) ES2808849T3 (enExample)
FR (1) FR3017299B1 (enExample)
IL (1) IL246941B (enExample)
JO (1) JO3522B1 (enExample)
MX (1) MX378781B (enExample)
RU (2) RU2697086C2 (enExample)
SG (2) SG10201907367QA (enExample)
WO (1) WO2015121348A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
DK3402480T3 (da) 2016-01-11 2021-06-28 Epicentrx Inc Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon
CN108697733A (zh) 2016-01-11 2018-10-23 鲁比厄斯治疗法股份有限公司 与癌症适应症的多模式治疗性细胞体系有关的组合物和方法
MX2018014929A (es) 2016-06-02 2019-08-26 Sanofi Sa Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa.
MX2020000265A (es) 2017-07-07 2020-07-22 Epicentrx Inc Composiciones para la administración parenteral de agentes terapéuticos.
EP3449935A1 (en) * 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
US11001826B2 (en) 2017-10-19 2021-05-11 Anticancer, Inc. Orally administered composition to lower serum methionine levels and method of use
CN111433193A (zh) 2017-12-01 2020-07-17 赛诺菲 药剂和能够结合至葡萄糖传感蛋白的部分的新型缀合物
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US20210403571A1 (en) 2018-11-15 2021-12-30 Erytech Pharma Synergistic combinations of methionine depletion agents and immune checkpoint modulators
JP2022530130A (ja) 2019-04-26 2022-06-27 ルビウス セラピューティクス， インコーポレイテッド 除核赤血球細胞を含む緩衝組成物
WO2020243006A1 (en) 2019-05-24 2020-12-03 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells
US20210147802A1 (en) 2019-11-04 2021-05-20 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using taurine or hypotaurine
EP4055149A1 (en) 2019-11-04 2022-09-14 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using myo-inositol
AU2021270347A1 (en) 2020-05-11 2022-12-15 Erytech Pharma Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof
TW202241471A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 提高個體中NKp30陽性淋巴球的方法及其用途
TW202241470A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 治療人類個體腫瘤之方法
TW202304482A (zh) 2021-03-14 2023-02-01 美商盧比亞斯治療公司 於個體中增加nkg2d陽性淋巴球之方法及其用途
AU2022279241A1 (en) * 2021-05-21 2023-11-30 Syntis Bio, Inc. Engineered methionine gamma lyase variants
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法
CN113481253B (zh) * 2021-06-09 2022-05-24 连云港杰瑞药业有限公司 生物催化制备磷酸吡哆醛的方法
WO2023067200A1 (en) 2021-10-24 2023-04-27 Erytech Pharma Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer
WO2025219395A1 (en) 2024-04-16 2025-10-23 Chu D'angers Treatment of cancers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1354204A (fr) 1963-01-22 1964-03-06 Auxiliaire De L Entpr Soc Dispositif de prévention d'accident pour benne de chargement notamment d'une bétonnière
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US5631271A (en) * 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US5254572A (en) * 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
CN1135264C (zh) 1997-03-13 2004-01-21 盐野义制药株式会社 制备L-甲硫氨酸γ-裂合酶晶体的方法
AU2002211512A1 (en) * 2000-10-06 2002-04-15 Millennium Pharmaceuticals, Inc. 25219, a novel human aminotransferase and uses therefor
CA2534995A1 (en) * 2003-07-31 2005-05-19 Anticancer, Inc. The use of plp with peg-rmetase in vivo for enhanced efficacy
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
FR2884717B1 (fr) * 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
RU2362572C2 (ru) * 2007-07-17 2009-07-27 Юрий Георгиевич Каминский Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
FR2925339B1 (fr) 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
ES2405258T3 (es) 2008-02-13 2013-05-30 Erytech Pharma Formulación y procedimiento para la prevención y el tratamiento de la manifestación esquelética de la enfermedad de Gaucher
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
CN101429506A (zh) * 2008-12-15 2009-05-13 吉林大学 基于红细胞载体的fish-in-net固定化酶
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
ES2600932T3 (es) 2009-10-27 2017-02-13 Erytech Pharma Composición para inducir una tolerancia inmunitaria específica
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion

Also Published As

Publication number Publication date
KR20160121532A (ko) 2016-10-19
EP3718562A1 (en) 2020-10-07
SG10201907367QA (en) 2019-09-27
MX378781B (es) 2025-03-11
RU2697086C2 (ru) 2019-08-12
KR102354103B1 (ko) 2022-01-24
EP3104875B1 (en) 2020-05-06
CN111358941A (zh) 2020-07-03
CA2938469A1 (en) 2015-08-20
EP3104875A2 (en) 2016-12-21
IL246941B (en) 2019-09-26
FR3017299B1 (fr) 2018-05-18
WO2015121348A2 (en) 2015-08-20
ES2808849T3 (es) 2021-03-02
AU2018201237B2 (en) 2019-09-26
CN106255506A (zh) 2016-12-21
FR3017299A1 (fr) 2015-08-14
JO3522B1 (ar) 2020-07-05
RU2016133315A3 (enExample) 2018-09-26
JP2017506260A (ja) 2017-03-02
US10046009B2 (en) 2018-08-14
AU2018201237A1 (en) 2018-03-15
RU2744659C2 (ru) 2021-03-12
MX2016010235A (es) 2016-10-28
RU2019123935A (ru) 2019-10-03
IL246941A0 (en) 2016-09-29
BR112016017337B1 (pt) 2022-08-09
WO2015121348A3 (en) 2015-10-08
CN111358941B (zh) 2023-12-01
BR112016017337A2 (enExample) 2017-08-08
AU2015217045A1 (en) 2016-08-18
US20180344771A1 (en) 2018-12-06
RU2016133315A (ru) 2018-02-16
CN106255506B (zh) 2020-04-14
AU2015217045B2 (en) 2018-03-08
US20160361361A1 (en) 2016-12-15
US10780126B2 (en) 2020-09-22
CA2938469C (en) 2023-03-14
US20210008114A1 (en) 2021-01-14
US11458170B2 (en) 2022-10-04
JP6563958B2 (ja) 2019-08-21
SG11201606264SA (en) 2016-08-30
RU2019123935A3 (enExample) 2020-03-26

Similar Documents

Publication Publication Date Title
IL258931A (en) Therapeutic compounds and methods
EP3447085A4 (en) CELLULOSIC RESIN COMPOSITION AND CELLULOSE COMPONENT
IL246941A0 (en) A pharmaceutical preparation containing erythrocyte thermalizing plp-dependent enzyme and its cofactor
PL3423105T3 (pl) Koniugaty przeciwciało-lek oparte na erybulinie i sposoby zastosowania
EP3436482A4 (en) ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
IL258082B (en) History of benzaimidazole and pharmaceutical preparations containing them
HUE053619T2 (hu) Anti-CD123 antitestek és konjugátumok és ezek származékai
EP3500255A4 (en) PHARMACEUTICAL COMPOSITIONS FOR EYE AND RELATED USE
ES2715251R1 (es) Novedosa composicion farmaceutica que comprende particulas que comprenden un complejo de un polirribonucleotido de doble cadena y una polialquilenimina
EP3355847A4 (en) ASEPTIC COMPOSITION OF PHARMACEUTICAL CONTAINERS
EP3341007A4 (en) MALT1 INHIBITORS AND USES THEREOF
BR112017016465A2 (pt) composto heterocíclico e composição farmacêutica que o compreende
EP3434285A4 (en) PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
EP3463345A4 (en) PHARMACEUTICAL COMBINATIONS
EP3405044A4 (en) BIOKONSERVATION COMPOSITION FOR FOODSTUFFS AND USES THEREOF
BR112016028188A2 (pt) embalagens e método de fabricação da mesma
PT3320903T (pt) Composição farmacêutica contendo amlodipina, valsartan e rosuvastatina
FI20155027A7 (fi) Polymyksiinijohdannainen ja sen käytöt
MA49837A (fr) Compositions pharmaceutiques
PL3145508T3 (pl) Nanocząstki klewidypiny i ich kompozycje farmaceutyczne
EP2994197A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
PL3480200T3 (pl) Aktywna optycznie pochodna piranochromenylofenolu i kompozycja farmaceutyczna ją zawierająca
FI20145984A7 (fi) Substituoitua bentsofurokinolitsiinia ja ɑ2-adrenergista agonistia käsittävät koostumukset
EP3302513A4 (en) COMPOSITION AND USES THEREOF
FI20155009A7 (fi) Pakkausaihio ja pakkaus